Sana Biotechnology Inc. (NASDAQ:SANA) is one of the best emerging technology stocks to invest in. On December 8, Sana Biotechnology announced the publication of groundbreaking preclinical data in the ...

CRISPR became big in 2025, bringing advances for serious Indian health risks, which will continue in the coming year ...

CRISPR Therapeutics (NASDAQ: CRSP) soared a few years ago, climbing more than 200% from the start of 2020 through early 2021, ...

Wondering if CRISPR Therapeutics is still a high risk biotech story or a quietly mispriced opportunity? This breakdown will help you decide whether the current share price makes sense for a long term ...

Here is the full list of the biotech and pharma Startup Battlefield 200 selectees, along with a note on what made us select ...

A dire wolf de-extinction debate, CRISPR-GPT for gene editing, and more topped the list of our most popular stories in ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Earlier in the week, ARK purchased 10,353 shares of CRISPR on Wednesday, valued at $584,530, and 43,333 shares on Tuesday, totaling $2,509,414. This consistent buying pattern suggests a strong ...

CRISPR Therapeutics shares early autoimmune and lymphoma data for zugo-cel, showing strong responses, manageable safety, and expanded oncology plans.

Gene editing has rapidly evolved into a transformative class of technologies that allow scientists to precisely insert, ...

One important metric to look for in a stock is an 80 or higher Relative Strength Rating. CRISPR Therapeutics CRSP now clears that threshold, with a jump from 79 to 82 Tuesday. Please watch the video ...

The EPA is the authority charged with regulating biosafety and genome editing. Its tasks include granting permits, conducting risk assessments, and overseeing compliance. On the other hand, the Bio ...